Ascentage Pharma Group International (AAPG) AI Stock Analysis

Ascentage Pharma Group International is a clinical-stage biotechnology company based in Suzhou, China, developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases. Its primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. Other pipeline candidates include APG-2575, APG-115, APG-1252, APG-1387, and APG-5918, which address hematologic malignancies, solid tumors, and chronic HBV. The company also operates clinical trials, provides science promotion services, engages in venture capital investment, and maintains strategic partnerships with pharmaceutical companies, research institutions, and Peking University.

Annual revenue fluctuated significantly, moving from $27.9M in FY2021 to $209.7M in FY2022 and $222.0M in FY2023. Revenue peaked at $980.6M in FY2024, representing growth of 341.8%, before falling 43.1% to $558.5M in FY2025. Gross margin declined from 97.0% in FY2024 to 76.4% in FY2025. Ascentage has operated at a net loss across all reported periods, with net income worsening from -$405.4M in FY2024 to -$1.21B in FY2025 as R&D expense reached $1.08B. For the trailing twelve months ended June 30, 2026, revenue stood at $642.6M, supported by latest quarterly revenue growth of 29.3% year-over-year, while TTM net margin was -228.5%.

As of June 30, 2026, Ascentage held $1.90B in cash and short-term investments against total debt of $2.10B, resulting in net debt of $199.1M. The company reported shareholders' equity of $556.6M, yielding a debt-to-equity ratio of 3.76 and a current ratio of 1.22. Cash burn remained significant, with FY2025 operating cash flow of -$1.17B and free cash flow of -$1.20B. During FY2025, cash deployment included capital expenditures of $27.6M and share buybacks of $9.0M, while the share count increased 486.4% over five years.

At a share price of $15.37 as of October 16, 2026, Ascentage carries a market capitalization of $1.44B and an enterprise value of $1.50B. The stock trades at a forward P/E of 10.1x, which is below the median of its US-listed Healthcare peers of 17.3x, and a price-to-sales ratio of 2.2x compared to the peer median of 4.1x. Its price-to-book ratio is 17.5x, and EV-to-revenue is 15.7x. Over the past year, the shares returned -57.8%, underperforming the S&P 500 (SPY) return of 16.8%.

Wall Street coverage consists of 7 Strong Buy ratings, 3 Buy ratings, and no Hold or Sell recommendations. The mean price target is $43.27, representing an upside of 181.5% compared to the last close of $15.37. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $677.6M and an EPS of -$1.18. For the next fiscal year, 6 analysts anticipate revenue of $1.44B and EPS of -$0.65. Over the last 4 quarters, Ascentage has beaten EPS estimates 1 time.

This page is an AI-written research summary of Ascentage Pharma Group International (AAPG). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AAPG income statement, AAPG balance sheet, AAPG key metrics, AAPG analyst forecast, AAPG chart. See the AAPG stock overview for the latest quote and news.